|
AU2019222350A1
|
|
Oral ingestion composition
|
|
WO2016010093A1
|
|
Method for producing composite containing amorphous curcumin and/or analogue thereof
|
|
WO2015174475A1
|
|
Composition for oral intake
|
|
JP2016204264A
|
|
Oxidized modified ldl complex inhibitor
|
|
JP2015010074A
|
|
Composition for oral ingestion
|
|
JP2012149004A
|
|
Activator of nuclear receptor
|
|
JP2010260816A
|
|
Cardiac function improvement by curcuma dye composition
|
|
JP2010248119A
|
|
Curcumin analog having therapeutic or preventive effect on parasitic disease
|
|
JP2010247839A
|
|
Container and method for modifying coffee powder
|
|
JP2010111587A
|
|
Pxr-activating agent
|
|
JP2010106001A
|
|
Ppar activator
|
|
JP2010100545A
|
|
Activation enhancer of nuclear receptor and/or transcription factor
|
|
JP2010100551A
|
|
Activator of nuclear receptors ppar alpha, ppar delta and rxr
|
|
EP2130829A1
|
|
Novel hydroxyindole derivative
|
